Orion Corporation

Finlande


 
Quantité totale PI 596
Quantité totale incluant filiales 625 (+ 29 pour les filiales)
Rang # Quantité totale PI 2 183
Note d'activité PI 3,3/5.0    328
Rang # Activité PI 2 178
Activité incl filiales 2,9/5.0    329
Symbole boursier
ISIN FI0009014369
Capitalisation 6.2000003B  (EUR)
Industrie Drug Manufacturers - Specialty & Generic
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

61 31
41 35
94 104
230
 
Autres noms
  • Orion Oyj
Dernier brevet 2025 - Stable pharmaceutical compositio...
Premier brevet 1981 - 4-benzyl- and 4-benzoyl-substitu...
Dernière marque 2025 - PRONAXEN
Première marque 1986 - DORMOSEDAN

Filiales

1 subsidiaries with IP (29 patents, 0 trademarks)

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Pharmaceutical preparations containing naproxen..
P/S Pharmaceutical products; vitamin preparations; nutritional supplements..
P/S Pharmaceutical preparations for the treatment of epilepsy..
2024 P/S Vitamins, trace minerals and nutritional supplements.
P/S Medical plasters containing lidocaine..
P/S Dental care preparations for animals; non-medicated hair shampoos; shampoos for pets [non-medica...
P/S Pharmaceutical preparations for the treatment of parkinson's disease and syndrome; transdermal pa...
P/S Pharmaceutical preparations for the treatment of Parkinson's disease and syndrome; transdermal pa...
P/S Pharmaceutical preparations for the treatment of Parkinson's disease and syndrome; transdermal p...
P/S Pharmaceutical preparations for the treatment of parkinson's disease and syndrome; transdermal p...
P/S Pharmaceutical preparations; nutritional supplements.
P/S Dental care preparations for animals; Non-medicated hair shampoos; Shampoos for pets [non-medicat...
P/S Pharmaceutical preparations for human use.
P/S Pharmaceutical preparations for human use for the treatment of schizophrenia.
P/S Pharmaceutical preparations to treat respiratory disorders. Medical inhalers.
Invention Stable pharmaceutical compositions of a cyp11a1 inhibitor. The present invention relates to a pha...
P/S Pharmaceutical preparations.
P/S Pharmaceutical preparations.
P/S Pharmaceutical preparations..
Invention 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperid...
P/S Nutritional supplements containing iron..
P/S Pharmaceutical preparations for the treatment of Parkinson's disease and syndrome.
P/S Pharmaceutical preparations containing pregabalin; medical and veterinary preparations containin...
P/S Pharmaceutical preparations containing pregabalin; medical and veterinary preparations containing...
P/S Pharmaceutical preparations for human use, namely, allergy medication.
Invention Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors. Compounds of formu...
P/S Pharmaceutical preparations for the treatment of neurological and neurodevelopmental disorders..
P/S Pharmaceutical preparations. Medical equipments.
P/S Pharmaceutical preparations; pharmaceutical preparations for the treatment and alleviation of ast...
P/S Pharmaceutical, veterinary and sanitary preparations; drugs for medical use.
P/S Pharmaceutical preparations for the treatment of Parkinson's disease and syndrome.
Invention Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormon...
Invention Cbl-b inhibitors. 123 3 are as defined in claim 1, or a pharmaceutically acceptable salt thereof....
Invention Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine ...
2023 P/S Pharmaceutical preparations for veterinary use, namely, sedatives and analgesics
P/S Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes;...
Invention Tasipimidine and cyp2d6 inhibitor combination treatment. The invention relates to co-administrati...
Invention Antibody discovery and development method. A method to introduce a mutation to a variable domain ...
Invention Use of levodopa, carbidopa and entacapone for treating parkinson's disease. The present disclosu...
Invention A method for determining a physical state of a subject, a data processing apparatus and a system....
Invention Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist. The present di...
Invention Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist. HH-imi...
Invention Pharmaceutical composition of a cyp11a1 inhibitor. The present invention relates to a pharmaceuti...
2022 Invention Cyp11a1 inhibitors. The present invention relates to a compound of formula (I) wherein A, B, R1,...
Invention Cyp11a1 inhibitors. 123455 are as defined in claim 1, or pharmaceutically acceptable salts thereo...
Invention Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor. The present invention relates to no...
Invention Cyp11a1 inhibitor for use in the treatment of prostate cancer. The invention relates to the use o...
Invention Process for the preparation of a cyp11a1 inhibitor and intermediates thereof. The present invent...
Invention Process for the preparation of a cyp11a1 inhibitor and intermediates thereof. The present inventi...
Invention Tead inhibitors. The present invention relates to a compound of formula (I) The present invent...
Invention Tead inhibitors. The present invention relates to a compound of formula (I) wherein A, Z, L, R1, ...
Invention Tead inhibitors. 123453333 are as defined in claim 1, or a pharmaceutically acceptable salt there...
Invention Tasipimidine formulations and use thereof. The present disclosure relates to a pharmaceutical co...
Invention Tasipimidine formulations and use thereof. The present disclosure relates to a pharmaceutical com...
Invention Stable pharmaceutical compositions of metformin. The invention relates to pharmaceutical composit...
Invention Novel salt forms of a 4h-pyran-4-one structured cyp11a1 inhibitor. The present invention relates...
Invention Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor. The present invention relates to n...
Invention Novel salt forms of a 4h-pyran-4-one structured cyp11a1 inhibitor. The present invention relates ...
Invention Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor. The present invention relates to no...
Invention Process for the preparation of a cyp11a1 inhibitor and intermediates thereof. HHH-pyran-4-onc (II...
Invention Inhaler
2021 Invention Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality. The prese...
Invention 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and simila...
Invention Cyp11a1 inhibitors. The present invention relates to compounds of formula (I) and (II) The pre...
Invention Method for the preparation of androgen receptor antagonists and intermediates thereof. The prese...
Invention Stable pharmaceutical compositions of ropinirole. The invention relates to pharmaceutical aqueou...
2020 Invention Pyridine oxynitride, preparation method therefor and use thereof. The present invention belongs ...
Invention Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide. The...
Invention Pharmaceutical composition of darolutamide. The present invention relates to a pharmaceutical co...
Invention Packaging box